InSilico Medicine Cayman TopCo

The commercialization of AI-driven drug development continues to move forward. Insilico Medicine announced a partnership to build a generative biology foundation model focused on biologic design and target optimization. The 2026 European Society for Medical Oncology annual meeting will open from October 23 to 27, featuring 28 breakthrough clinical studies led by or deeply involving China, of which 4 were selected for oral presentation in the plenary session, accounting for one-third of the total. In the pharmaceutical segment, 29 late-breaking abstract trial drugs were originally developed or co-developed by domestic Chinese pharmaceutical companies, covering multiple frontier areas including antibody-drug conjugates, bispecific antibodies, and EGFR-TKI-resistant non-small cell lung cancer. Guosheng Securities noted that the radiopharmaceutical sector recently saw two major deals: Telix acquired ITM for 1.65 billion US dollars, and Borui Chuanghe signed a collaboration with Novartis worth up to 900 million US dollars. Meanwhile, Ionis' oligonucleotide therapy Ulefnersen met its primary endpoint in a Phase III study for FUS-ALS, providing the first effective treatment option for this rare disease. As of August 31, 2026, the top ten weighted stocks in the SSE STAR Market Biomedical Index accounted for 51.54% of the total, namely United Imaging Healthcare, BeiGene, Allist Pharmaceuticals, Baili Tianheng, Zelgen Biopharmaceuticals, RemeGen, iRay Technology, Huitai Medical, Junshi Biosciences, and MGI Tech.

Insilico Medicine has dosed the first patient with Rentosertib, also known as ISM001-055 or INS018_055, in GENESIS-IPF-3, the world's first Phase III clinical trial of a generative AI-driven innovative drug, at Peking Union Medical College Hospital, with Shanghai Pulmonary Hospital enrolling its first patient the same day. The 52-week prospective, multi-center, randomized, double-blind, placebo-controlled, parallel-group study is expected to enroll a total of 320 participants across 47 centers in China, with a primary endpoint of the annual rate of decline in forced vital capacity and a key secondary endpoint of time to first occurrence of any disease progression event. The trial is led by Professor Zuojun Xu of Peking Union Medical College Hospital, Chinese Academy of Medical Sciences as Leading Principal Investigator, with Academician Nanshan Zhong of the Chinese Academy of Engineering and President Chang Chen of Shanghai Pulmonary Hospital as Co-Leading Principal Investigators. Insilico recently reported total revenue of approximately $106 million in the first half of 2026, a 287% year-over-year increase, and its first profitable half-year since listing, with an adjusted net profit exceeding $51 million, while the total contract value of transactions announced in 2026 reached approximately $7.3 billion, pushing the cumulative contract value of its major collaborations since 2021 to approximately $11 billion. Rentosertib, a potentially first-in-class small molecule targeting TNIK, received Orphan Drug Designation from the U.S. Food and Drug Administration for IPF in February 2023 and remains investigational, having not been approved by any regulatory authority.

Insilico Medicine has launched its Virtual Aging Cell webpage and previewed a multi-agent driven platform that uses biological age as a core condition for simulating cellular dynamics. The platform deploys agent swarms across six biological scales—molecular, intracellular, intercellular, tissue, organ, and organism—to model differentiation, reprogramming, and aging, aiming to support target identification and drug discovery. The launch follows a decade of work including the PreciousGPT model series, with the company noting it has nominated 33 preclinical candidates since 2021, 13 of which have received IND approvals or clearances. Insilico will present further details at the ARDD 2026 conference in Boston.

Investment in AI-driven drug discovery has surged past $2 billion as the technology cuts development timelines by 70% and doubles clinical success rates, according to a new BCC Research report. The report finds that AI reduces the traditional 4-to-5-year discovery phase to 12-to-18 months while lowering R&D costs by 30% to 40%. AI-validated targets show a 2.5 times greater probability of progressing through clinical development, with regulatory approval rates rising from 10-to-15% to 20%. The United States accounts for 60% of global investment, with major funding rounds including Generate: Biomedicines at over $500 million, Exscientia at over $500 million, and Kailera Therapeutics with a $600 million Series B. Key players include Atomwise, Exscientia, Generate: Biomedicines, Iambic Therapeutics, Recursion, Schrödinger, Insilico Medicine, and Benevolent AI, alongside pharmaceutical giants Pfizer and Bayer.

Insilico Medicine Cayman TopCo expects first-half 2026 net profit between approximately $33.5 million and $39.5 million, driven by revenue growth from out-licensing, co-development, and research collaborations. Revenue is projected in the range of approximately $102.5 million to $106.5 million, a year-on-year increase of approximately 272.7% to 287.3%. The company also initiated a Phase III clinical trial of Rentosertib, its lead AI-powered investigational candidate for idiopathic pulmonary fibrosis, which will enroll 320 participants across 47 centers in China. Rentosertib is the first asset from Insilico's AI-driven pipeline to enter a Phase III trial and previously received Orphan Drug Designation from the U.S. Food and Drug Administration in February 2023. Insilico shares rose 10.86% to HK$41.02 following the announcements.

The Sci-Tech Innovation Board Medical ETF Huaxia has recorded net capital inflows for nine consecutive trading days, totaling 125 million yuan, with an average daily net inflow of 13.85 million yuan. In related news, the newly added negotiated drugs in the 2025 medical insurance drug catalog have been stocked at 310,000 designated medical institutions, with over 12 million patient visits using the new additions. From January to May, national medical insurance fund spending on related new drugs reached 2.636 billion yuan, driving drug sales of 3.946 billion yuan. The first commercial insurance innovative drug catalog included 19 drugs, and as of the end of May, they have been stocked at 1,486 designated medical institutions, with over 100 inclusive insurance products covering drugs in the catalog. The National Healthcare Security Administration stated that adjustments to this year's medical insurance catalog and commercial insurance innovative drug catalog have begun, with a total of 818 application materials received, and the new catalogs are expected to be released in November. Guosheng Securities noted that domestic innovative drugs are actively engaging in external collaborations. Insilico Medicine reached a deal with Takeda worth up to approximately 600 million US dollars, while CSPC Pharmaceutical Group reached a deal with AstraZeneca worth up to 1.77 billion US dollars. The overseas expansion is extending from single-product licensing to platform capability output, including AI-driven drug discovery and small nucleic acid delivery.

Servier's head of business development Frederic Scaerou discussed the company's merger and acquisition and manufacturing strategy in a Pharmaceutical Technology podcast. The French pharma company completed the $2.5 billion acquisition of oncology developer Day One Biopharmaceuticals and acquired the muscular dystrophy business of Edgewise Therapeutics for around $2.65 billion in 2026. These moves followed major artificial intelligence-focused deals with InSilico Medicine and Iktos. Scaerou explained how these transactions are shaping Servier as it navigates shifting global industry trends.

The innovative drug sector has staged a strong rebound after an earlier correction, with the SSE STAR Market Biomedical Index rising 1.10%. In the first half of 2026, the total value of China's out-licensing deals approached 100 billion US dollars, and Chinese pharmaceutical companies occupied eight of the top ten global pharmaceutical transactions, indicating that the trend of innovative drugs going overseas remains robust. Guosheng Securities noted that domestic innovative drugs continue to see active external collaborations, and platform-based technological capabilities are gaining broad recognition from overseas multinational corporations. Landmark deals such as Insilico Medicine with Takeda and CSPC Pharmaceutical Group with AstraZeneca signal that Chinese pharmaceutical companies are upgrading from single-product licensing to the out-licensing of underlying technology platforms. The Sci-Tech Innovation Board Healthcare ETF Harvest closely tracks the SSE STAR Market Biomedical Index, which selects 50 large-cap biomedical industry leaders from the STAR Market, with the top ten constituents accounting for a combined weight of 51.84%.

Insilico Medicine has entered into a strategic collaboration with Takeda Pharmaceutical to advance novel drug candidates across Takeda's therapeutic areas. The partnership will leverage Insilico's proprietary Pharma.AI platform to identify clinically differentiated molecules, with Insilico leading AI-driven discovery and Takeda handling clinical validation and global development. Financial terms include approximately $60 million in upfront and near-term payments to Insilico, with success-based milestones that could bring the total deal value to about $600 million, plus tiered royalties on future sales. Takeda will hold exclusive worldwide rights to develop, manufacture, and commercialize any resulting therapeutics.

The Healthcare Technology and Innovation index added three companies during its quarterly rebalance on June 19: CRISPR Therapeutics, Insilico Medicine, and Compass Pathways. CRISPR Therapeutics co-developed CASGEVY, the only viable gene-editing cure for sickle cell disease and beta-thalassemia, and is advancing therapies for cardiovascular and autoimmune diseases. Insilico Medicine is the first pure-play AI drug discovery company in the index, generating 6 to 8 preclinical candidates annually and projecting $1,287MM in FY 2026 revenue. Compass Pathways joined following final large-scale trials of COMP360, a synthetic psilocybin treatment that provided three to six months of relief for treatment-resistant depression.

Insilico Medicine has signed a partnership with South Korea's SK Biopharmaceuticals to develop new drugs for neuroimmune conditions in a deal valued at more than $2.5 billion. Insilico will use its Pharma.AI platform to design new candidates, while SK Biopharmaceuticals will handle late-stage development and commercialization. The Hong Kong–listed company is set to receive $18 million in near-term payments, with the potential to earn up to $2.5 billion upon reaching certain development and commercial milestones, plus royalties. This is Insilico's largest tie-up with an Asia-Pacific partner and its second deal of this magnitude with a major pharmaceutical company, following a $2.75 billion agreement with Eli Lilly in late March. Insilico's shares rose 5.6% in Hong Kong trading on Monday after the announcement, while SK Biopharmaceuticals' shares dropped 1.7%.